Actualités

2020/05 - CRISALIS Publication #Dupilumab #Severe asthma #Program of early access to use

Publication by CRISALIS / F-CRIN network members of French "real-life" data obtained under the temporary authorization for nominal use (ATUn) of dupilumab for uncontrolled severe asthma patients with no available treatment option left. The use of dupilumab in this indication was then validated by the European Commission in March 2019.

 

Click on "Read more" below to more about the results published in this publication.

English

2020/04 - CRISALIS Publication - #mepolizumab #eosinophilic severe asthma #national early access program

Publication by CRISALIS members of French "real-life" data obtained under the temporary authorization for nominal use (ATUn) of mepolizumab for severe eosinophilic asthmatics, a program that preceded commercialization.

 

Click on "Read more" below to find out more, access the publication summary and, to go even further access to the original article.

 

 

 

 

 

English